Almonty Industries: Analysts raise target price! 75% Upside Potential! CEO clearly backs Rheinmetall and Co. on CNBC
Anything other than further price increases for Almonty shares in the coming weeks would be a surprise. The tungsten gem is facing a hot summer. The main driver for the share price will be the commissioning of the mega mine in South Korea. Due to the increasing visibility of revenue and profit growth, analysts have significantly raised their price targets for the share. With its unique market position, the Company remains attractively valued compared to its peers. With the planned upcoming NASDAQ listing, the stock is expected to attract greater attention from US investors. That Almonty is gaining more visibility is underscored by CEO Lewis Black's recent interview with CNBC. In it, Black emphasized that Almonty already supplies 85% of its production to the defense sector. Rheinmetall, for example, needs tungsten to harden ammunition. 75% price potential: Analysts raise target
GBC Research has raised its price target for Almonty Industries (TSX:AII) shares from CAD 4.20 (EUR 2.69) to CAD 5.50 (EUR 3.52). The 'Buy' recommendation was confirmed in a detailed research update.
The main reason for the price target increase is the improved visibility for the commissioning of the Sangdong mine in South Korea. The mega mine will make Almonty the largest tungsten producer in the Western world. Analysts report that construction work on the Sangdong mine was largely completed in the first quarter. The installation of the processing plant is in its final phase, and the last tranche of the project financing loan from KfW IPEX Bank for USD 75.1 million has been drawn down. The first ore processing is scheduled to take place in the second half of the year. Analysts expect strong growth in key figures Source: GBC Research P/E ratio for 2027 below 5
Revenue and earnings are expected to grow dynamically in the coming years. Analysts already expect revenue to double to around CAD 60 million this year. In 2027, revenue of CAD 314 million is expected to result in net income of CAD 212 million. This would give Almonty a strong net margin of 67.5%. With expected earnings per share of CAD 0.74 for 2027, the P/E ratio is currently below 5. This appears to be too cheap. GBC study available for download here Almonty of strategic importance for the defense sector
With its resource base, high ore grades, and vertical integration extending to its tungsten oxide processing plant, Sangdong is becoming a strategically significant player in the global tungsten supply chain – and thus for the Western defense sector. This strategic importance was recently confirmed officially at the highest level by the US government. Almonty received an official letter from the US House of Representatives' Select Committee on the Strategic Competition between the United States and China. The Sangdong mine was recognized by the committee for its potential to become the largest tungsten producer outside China.
The committee intends to continue working with Almonty. Almonty could not only support the US defense industry but also potentially supplement national defense stocks with its tungsten. There has been no commercial tungsten production in the US since 2015.
CEO Lewis Black emphasized Almonty's focus on supplying the defense industry in an interview with CNBC last Friday. According to Black, nearly 85% of current production – Almonty already operates a tungsten mine in Portugal – is already going to the defense sector. This focus will be maintained with the opening of the Sangdong mine. Black also explained the relocation of the Company's headquarters from Canada to the US – a move that had already been decided under the Biden administration – by saying that the Company wanted to be closer to its customers.
(link:
The fact that there is a lower price limit but no upper limit for the latest partnerships and purchase agreements shows that availability is more important to customers than price. The lower limit, in turn, gives Almonty important planning security.
Overall, the lights are green for further price increases for Almonty shares. GBC Research's forecasts show that the stock is anything but expensive, even after tripling since the beginning of the year. This is also true when compared to companies like Rheinmetall, Germany's largest defense manufacturer, which, for example, requires tungsten for hardening ammunition, or the US raw materials company MP Materials. The comparison with MP Materials will likely come into sharper focus with the upcoming NASDAQ listing. By then at the latest, the share price should be heading towards GBC's price target. An entry at the current level appears to offer significant upside potential. Almonty shares with a clear upward trend Source: Refinitiv Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as 'Relevant Persons') may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a 'Transaction'). 'Transaction'). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies. Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
This is third-party provided content issued on behalf of Almonty Industries, please see full disclaimer here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
35 minutes ago
- Winnipeg Free Press
S&P/TSX composite ends lower, U.S. stock markets mixed
TORONTO – Canada's main stock index lost steam through the trading day on Friday to close lower, while U.S. stock markets were mixed. The S&P/TSX composite index was down 8.43 points at 26,497.57. In New York, the Dow Jones industrial average was up 35.16 points at 42,206.82. The S&P 500 index was down 13.03 points at 5,967.84, while the Nasdaq composite was down 98.86 points at 19,447.41. The Canadian dollar traded for 72.84 cents US compared with 72.87 cents US on Thursday. The August crude oil contract was up 34 cents US at US$73.84 per barrel and the July natural gas contract was down 14 cents US at US$3.85 per mmBTU. The August gold contract was down US$22.40 at US$3,385.70 an ounce and the July copper contract was down two cents US at US$4.83 a pound. This report by The Canadian Press was first published June 20, 2025. Companies in this story: (TSX: GSPTSE, TSX: CADUSD)
Globe and Mail
an hour ago
- Globe and Mail
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Specifically, Nasdaq cited the issuance of Series C voting convertible preferred stock and warrants to the Company's placement agent and advisor to those transactions, as having been structured in a way that triggered these rule violations. The Company was notified by the Hearings Panel of its determination to delist the Company's common stock effective today. Lipella is disappointed by this decision—particularly in light of the fact that it was taking immediate steps to obtain stockholder approval and address the concerns raised by Nasdaq. Lipella remains operationally sound, and its business fundamentals are intact. The Company is executing on its strategic and clinical development plans, including continued advancement of its lead product candidates LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus. In parallel, Lipella is actively exploring other markets to list its common stock and is committed to relisting its shares on a trading venue that provides the best possible liquidity and access for investors. The Company's common stock is currently quoted on the OTC Markets under the symbol 'LIPO.' 'We acknowledge Nasdaq's decision and are focused on taking swift, constructive steps accordingly,' said Dr. Jonathan Kaufman, Chief Executive Officer of Lipella. 'Our commitment to our shareholders, our mission, and our clinical goals has not changed.' The Company remains a reporting company under the Securities Exchange Act of 1934 and will continue to file periodic reports and disclosures with the U.S. Securities and Exchange Commission. Lipella will keep its stockholders informed of all material developments as it continues to assess its options. About Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking Statements This press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, including with respect to the Company's exploration of all markets and its commitment to list its common stock, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT: Jonathan Kaufman Chief Executive Officer Lipella Pharmaceuticals Inc. Info@ 1-412-894-1853 PCG Advisory Jeff Ramson jramson@
Cision Canada
an hour ago
- Cision Canada
Thinkific Announces Results of Annual General Meeting of Shareholders
VANCOUVER, BC, June 20, 2025 /CNW/ - Thinkific Labs Inc. (" Thinkific" or the " Company") (TSX: THNC) is pleased to announce results from its annual general meeting of shareholders (the " Meeting") held today. At the Meeting, by resolutions passed by ballot vote, the seven (7) nominees proposed by management for election to the Board of Directors at the Meeting and listed in the Company's management information circular dated May 6, 2025, were elected. The directors will remain in office until the next annual general meeting of shareholders, or until their successors are elected or appointed. The results of the vote are set forth below: The final item of business at the Meeting was to appoint KPMG LLP, Chartered Professional Accountants (" KPMG"), as auditor of the Company for the ensuing year and to authorize the directors to fix the remuneration of the auditor. By resolution passed by ballot vote, KPMG was appointed as the auditor of the Company for the ensuing year. The results of the vote are set forth below: About Thinkific Thinkific (TSX: THNC) is an award-winning learning commerce platform where courses and community come together to power business growth. Thinkific gives academies, experts, and businesses everything they need to create and sell online learning experiences, build communities, and grow their revenue — all from one platform. More than 35,000 customers — including companies like GoDaddy, Nasdaq, ActiveCampaign, and Datadog — have generated billions in revenue using Thinkific, impacting more than 200 million people worldwide. For more information, please visit SOURCE Thinkific Labs Inc.
